License and Development Agreement

RNS Number : 9933X

Tekcapital plc

28 February 2017

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

28 February 2017

Tekcapital plc

("Tekcapital" or the "Company")

BELLUSCURA LTD ANNOUNCES OXYGEN CONCENTRATOR LICENSE AND DEVELOPMENT AGREEMENT

Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has signed a co-exclusive license and development agreement with Separation Design Group ("SDG") to develop a next generation portable oxygen concentrator ("POC").  As part of the agreement, Belluscura has licensed a portfolio of six intellectual properties from SDG¹ and has agreed to provide monthly funding towards the development of a prototype POC device.

A POC is a device used to deliver concentrated oxygen to a patient requiring oxygen therapy.  POCs are typically prescribed to people suffering from chronic obstructive pulmonary disease ("COPD"). The World Health Organization has estimated that 64 million people are suffering from moderate to severe COPD around the world².  POCs are generally considered a safer, less expensive and more convenient treatment for COPD compared to traditional compressed oxygen cylinders³.  Ambulatory patients can benefit from greater personal freedom, with most airlines permitting their use during flight.  The US Federal Aviation Authority requires all airlines landing in the USA to permit the use of approved POCs⁴.

SDG is a leading research laboratory in the field of oxygen concentrators.  The Directors believe that the license should allow Belluscura to access and develop a next generation POC based on SDG's significant intellectual property portfolio, covering such features as oxygen enrichment, portability, oxygen conditioning and convenient and cost-effective maintenance. 

Bob Rauker, Belluscura's CEO said: "We are delighted to enter into this license and development agreement. With the portable oxygen concentrator market expected to nearly double to $2.2bn by 2021⁵, we believe that this opportunity has the potential to advance Belluscura's mission of investing in undervalued technology in order to provide premium medical devices at affordable prices."

About Belluscura:

Belluscura Limited is a global medical device company founded in in Oxford, England.  Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines.  Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com.

Tekcapital owns approximately 65% of the share capital of Belluscura.

For further information, please contact:

Tekcapital Plc
Clifford M. Gross, Ph.D.	[e-mail]
Allenby Capital Limited (Nominated Adviser & Joint Broker)	[phone]
Jeremy Porter / Alex Brearley
Dowgate Capital Stockbrokers (Joint Broker)	[phone]
David Poutney / James Serjeant
Walbrook PR Ltd	[phone]
Paul Cornelius / Helen Cresswell / Sam Allen	[e-mail]

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85

Note 1

Patent Number	Priority Date (P)	Title
US 9,199,055 B2	P 11/24/2009	Ultra Rapid Cycle Portable Oxygen Concentrator
US 8,894,751 B2	P 11/24/2009	Ultra Rapid Cycle Portable Oxygen Concentrator
US Patent Application 14/876,133	P 11/24/2009	Ultra Rapid Cycle Portable Oxygen Concentrator
US 8,888,902	8/15/2012	Portable Oxygen Enrichment Device and Method of Use
US 8,500,852	4/30/2007	Sorption Method, Device, and System
US 7,291,271	12/09/2003	Meso-frequency traveling electro-kinetic continuous adsorption system

Note 2

http://www.who.int/respiratory/copd/en/

Note 3

http://www.inogen.com/resources/oxygen-concentrators/oxygen-tanks-vs-oxygen-concentrators/

Note 4

https://www.faa.gov/about/initiatives/cabin_safety/portable_oxygen/

Note 5

http://www.medgadget.com/2017/02/portable-oxygen-concentrator-market-size-at-744-million-in-2014-is-expected-grow-to-2-2-billion-by-2021.html

 

END

 

 

AGRZMGZZMNRGNZZ